GO
Loading...

Pharmaceuticals

More

  • Novartis sues India's Cipla over respiratory drug Onbrez Wednesday, 17 Dec 2014 | 8:22 AM ET

    MUMBAI, Dec 17- Swiss drugmaker Novartis AG said on Wednesday it had sued India's Cipla Ltd for infringing patents covering its respiratory drug Onbrez, a month after Cipla launched a copy at a fifth of the original drug's price. Cipla, India's fourth-largest drugmaker by revenue, launched its copy of Onbrez in New Delhi in October, citing urgent unmet need for the...

  • Lethal injection drug bill clears Ohio Legislature Wednesday, 17 Dec 2014 | 2:08 AM ET

    COLUMBUS, Ohio— The names of companies that provide Ohio with lethal injection drugs would be shielded under a proposal the state House is poised to vote on Wednesday. Problems finding supplies of lethal drugs have created a de facto moratorium on executions in Ohio, which a decade ago was one of the country's busiest death penalty states. Ohio executed just one...

  • SINGAPORE, Dec 17- Business sentiment among Asia's top companies rose in the fourth quarter with builders switching to most optimistic from least just three months earlier due in part to increased new orders, while property developers also showed a rise in sentiment. The Thomson Reuters/ INSEAD Asian Business Sentiment Index rose to 72 in the fourth quarter, up...

  • Eli Lilly bumps up dividend for first time since 2009 Tuesday, 16 Dec 2014 | 10:44 AM ET

    INDIANAPOLIS— Shares of Eli Lilly outpaced broader trading indexes Tuesday morning, a day after the drugmaker announced its first dividend increase in more than five years. That will raise the quarterly payout to 50 cents per share, or $2 annually. Eli Lilly and Co. shares climbed about 1 percent, or 71 cents, to $70.38 Tuesday, while the Standard& Poor's 500 index...

  • Judge halts Alzheimer's drug swap until July Monday, 15 Dec 2014 | 5:27 PM ET

    District Judge Robert Sweet told Dublin- based Actavis PLC to continue making the drug Namenda available for 30 days after generic alternatives become available on July 11 "in order to allow for an orderly transition." His injunction orders the company to inform doctors and pharmacists of the decision and tells Actavis not to impose any hurdles for filling...

  • Dec 12- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers. The deal stirred speculation that developers such as Cempra could also be takeover targets. I know a lot of other biotechs are, " Cempra Chief Executive Prabha Fernandes said in an...

  • ZURICH, Dec 12- Novartis said on Friday its experimental psoriasis drug Cosentyx was better at clearing the rough skin patches associated with the disease than Johnson& Johnson's Stelara. The data follows results last year showing Cosentyx, also known as secukinumab, was superior to Amgen's Embrel in a head-to-head study. Other drugmakers working on new...

  • TEL AVIV, Dec 11- Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling multiple sclerosis treatment Copaxone. There are two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta...

  • Dec 10- Walgreen Co said Chief Executive Greg Wasson would retire and hand the reins on an interim basis to the head of Alliance Boots Holdings Ltd, a move that follows a series of events that has tested investor confidence in the U.S. drugstore chain. Walgreen said Wasson would step down shortly after it completes the purchase of the 55 percent it does not already...

  • Arca's potential Ebola drug gets "orphan drug status" Wednesday, 10 Dec 2014 | 11:19 AM ET

    Dec 10- Arca Biopharma Inc said the U.S. Food and Drug Administration granted its experimental drug orphan drug status as a potential treatment for viral hemorrhagic fever after exposure to the Ebola virus. The Westminster, Colorado- based company, whose stock rose about 11 percent on Wednesday, joins a list of drugmakers looking for ways to fight the largest...

  • LONDON, Dec 10- Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development increasing for the first time since 2010.. So far this year the U.S. Food and Drug Administration, which acts as gatekeeper to the world's biggest market, has approved 35 new products, up from 27 in the whole of 2013...

  • CHICAGO, Dec 9- The U.S. Department of Health and Human Services on Tuesday offered liability protections to drugmakers rushing to develop Ebola vaccines and urged other countries to follow suit. Health and Human Services Secretary Sylvia Burwell made the announcement as part of the Public Readiness and Emergency Preparedness Act in a move aimed at...

  • Valeant to drop deal-making to cut debt, lift stock Tuesday, 9 Dec 2014 | 9:00 AM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    Valeant Pharmaceuticals is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt and boost its stock price.

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • Seattle Genetics CEO: Blockbuster cancer drug?  Monday, 8 Dec 2014 | 3:15 PM ET

    Clay Siegall, Seattle Genetics CEO, discusses the company's center focus on treating Non-Hodgkin's lymphoma. Siegall tells CNBC's Meg Tirrell he is excited about the impact of the new drug on patients.

  • Paid doctor consultants swayed to use pricey drugs? Monday, 8 Dec 2014 | 11:11 AM ET
    Lucentis, produced by Genetech.

    Doctors who used Genentech's expensive eye drug Lucentis were also among the highest-paid consultants for the company, reports the New York Times.

  • Cubist Pharm's shares soar on BIG Merck deal Monday, 8 Dec 2014 | 7:59 AM ET
    A researcher at a Cubist Pharmaceuticals lab.

    Drug giant Merck said it will buy Cubist and its slate of medicines administered in hospitals, many for bacterial infections, for about $9.5 billion.

  • Fighting cancer at ASH  Monday, 8 Dec 2014 | 7:42 AM ET

    CNBC's Meg Tirrell reports on hottest new technologies from the annual meeting of the American Society of Hematology.

  • WASHINGTON, Dec 8- About 30 seconds into an appearance before the U.S. Supreme Court this fall, lawyer Paul Clement was interrupted by a question. It came from Justice Elena Kagan, and it cut to the heart of his case. The exchange illustrates the familiarity that distinguishes a handful of lawyers from more than a thousand other attorneys who have appeared before...